A recent multicenter study in Japan highlights the long-term safety and efficacy of the iStent inject W device combined with phacoemulsification for treating open-angle glaucoma (OAG) in adults. Over a span of two years, this innovative treatment demonstrated significant reductions in intraocular pressure (IOP) and decreased dependency on glaucoma medications among patients.
Study Design and Methodology
The prospective, post-market surveillance study evaluated 214 eyes of Japanese adults diagnosed with OAG, including primary open-angle glaucoma (POAG), normal tension glaucoma (NTG), and exfoliative glaucoma (XFG). Patients underwent iStent inject W implantation alongside phacoemulsification, with assessments conducted at multiple intervals: Day 1, Week 1, and Months 1, 3, 6, 12, and 24 post-surgery. The primary metric for success was defined by maintaining IOP below preoperative levels without requiring additional glaucoma surgeries or medications.
Key Findings and Outcomes
Results indicated a high cumulative probability of success at the two-year mark, varying slightly among glaucoma subtypes. Overall, 91.7% of the cohort met the success criteria. Significant reductions in mean IOP and the number of glaucoma medications were observed consistently throughout the study period. Specifically, patients saw an average decrease of 2.0 mmHg in IOP and a reduction of nearly two medications by the end of two years. Additionally, medication costs were nearly halved, easing the economic burden on patients.
• High success rates across different glaucoma subtypes
• Sustained IOP reduction maintained over two years
• Nearly 50% decrease in monthly medication costs
• Minimal adverse events reported, ensuring patient safety
• Enhanced quality of life due to reduced medication dependency
The study underscores the effectiveness of the iStent inject W device in managing OAG among Japanese patients. With minimal adverse events and substantial reductions in both IOP and medication requirements, this treatment offers a promising option for long-term glaucoma management. Patients benefit not only from improved ocular health but also from decreased financial strain associated with ongoing medication use. Clinicians may consider integrating this procedure into their treatment protocols to enhance patient outcomes and adherence.
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.
